Friday, 20 April 2018 - 21:17
  • it
  • de
  • en
  • fr

Sanofi

Sanofi sells 12 drugs to Cooper-Vemedia for €158m

The Belgian daily der Standard has reported that Sanofi has sold 12 brands to Cooper-Vemedia for €158m. The sale is part of Sanofi’s strategy to simplify its product portfolio and fund its recent acquisitions. Cooper-Vemedia belongs to private equity Charterhouse…

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Sanofi invests €350m on new vaccine production plant

France-based Sanofi has confirmed this week a significant €350m (CA$500m) investment to build a vaccine production plant in its plant in Toronto, Canada. The new investment makes the Canadian site one of the main plants of the group, with over…

Advent Capital now about to acquire Sanofi’s Zentiva ($2bn)

Advent International is reportedly about to acquire Zentiva, Sanofi’s European arm marketing generics. Advent has beaten its competitor, the investor BC Partners, the Financial Times has reported. Private equities Blackstone and Nordic Capital have already pulled out from the race…

Sanofi seeks to restore leadership in diabetes treatments

Sanofi is trying to restore its leading position in diabetes treatments, like at the time when its insulin Lantus was among blockbusters. The France-based group is now largely focusing on sotagliflozin, which acts as a SGLT-1 and SGLT-2 inhibitor and…

M&A of Consumer Health units at a stalemate

The market provides with a wide range of opportunities those companies that want to enhance their Consumer Health portfolio through acquisitions. Assets are currently on sale by Germany-based Merck KGaA, intending to dismiss its Consumer Health arm for €4bn, and…

Sanofi about to sell know-how and R&D center to Evotec for €60m

Germany-based Evotec and its French competitor Sanofi yesterday announced they are in talks for an agreement to license to Evotec the know-how developed by Sanofi in infectious diseases. Sanofi’s package does not include any product currently marketed, while it does…

Sanofi Genzyme announces 130 staff cuts

Sanofi Genzyme has announced today it will dismiss 130 employees at Allston Landing plant in Boston. The decision reflects the need to cut prices and simplify production processes. Sanofi acquired the site in 2011, after acquiring Genzyme. Sanofi currently has…

Diabetes business increasingly struggling

In the past, the diabetes business used to deliver excellent margins and considerable growth rate, which encouraged many companies to join it and launch new products. Increased competition and pressure on prices by authorities have resulted in the current global-scale…

Battle over Ablynx begins

Bloomberg has reported that Denmark-based Novo Nordisk is preparing a new bid to acquire Belgium-based biotech Ablynx. The offer would significantly improve the previous one-€2.6bn-and could be submitted as early as next week. Ablynx has tried to enter into talks…

Why big pharma companies always create new spinoffs

The recent acquisitions in the pharma sector (Sanofi, Celgene, Biogen) have confirmed that the strategy adopted by many groups–i.e. spinning off part of their assets and divesting them–is the best way to grant shareholders a rich financial return. The most…

Confirmed: Sanofi buys Bioverativ for $11.6bn

Sanofi has announced today in the morning, before trading started, that it has acquired US-based Bioverativ for $11.6bn in cash, corresponding to $105 per share, that is a 64% premium over Friday night’s closing price. The deal enhances Sanofi’s hemophilia…

Sanofi about to acquire Bioverativ for $11.5bn (63% premium)

The Wall Street Journal yesterday reported, late at night, that France-based Sanofi is about to acquire Bioverativ Inc. for approximately $11.5bn, that is $105 per share, which would correspond to a 63% premium over last Friday’s closing price. Investors in…

Battle over Sanofi’s Zentiva ($2bn) begins

The Economic Times India yesterday reported that India-based Aurobindo, Zydus Cadila, Torrent Pharma and Intas are targeting Sanofi’s European generics business, which is managed by Czech subsidiary Zentiva. Zentiva is worth at least $1.5-$2.0bn, according to analysts, and has drawn…

Sanofi’s Toujeo bests Tresiba in clinical trial with 929 patients

Sanofi has announced today that its insulin Toujeo has met the primary endpoint vs Novo Nordisk’s insulin Tresiba (degludec) in the Bright clinical trial.  Bright has been conducted on 829 patients with type II diabetes and its complete results will…

Takeda announces clinical trial for anti-Zika vaccine

Japan-based Takeda has announced a Phase I clinical trial for its anti-Zika (TAK-426) vaccine. The trial will have a minimum duration of 15 months and will be partly funded by the US Department of Health and Human Services, the Office…

Sanofi–trade unions agreement on job cuts in Höchst (Frankfurt) site

Labor representatives at Sanofi’s Höchst (Frankfurt) site have reportedly reached an agreement with the company’s management. The agreement avoids the initially expected dismissals and only includes voluntary resignations. It involves 150 employees that will have to leave the company before…

M&A drive in pharma fading

Deals in pharma M&A in the first 9 months of the year totaled $66.4bn, equaling a 36% drop as compared to 2016. The decrease is even more significant when compared to 2015, when sales volume over the first three quarters…

Sanofi started the process to divest Zentiva

Sanofi is reported to have already sent a teaser to the potential bidders for Zentiva, including Stada group. Zentiva, however, has also attracted interest from some China-based PEs, and from other PEs such as Clayton Dubilier & Rice, CVC Capital…

Monthly review: October

October has brought interesting news in the pharmaceutical industry. Among the most significant news published in GoINPHARMA, the growing rumors on Amazon about to debut in healthcare surely rank first. The US-based distribution giant is likely to start launching drugs…